APELOA
APELOA, officially known as APELOA Pharmaceutical Co., Ltd., is a prominent player in the pharmaceutical industry, headquartered in China (CN). Founded in 2001, the company has established a strong presence in major operational regions across Asia and beyond, focusing on the development and manufacturing of high-quality generic drugs and active pharmaceutical ingredients (APIs). With a commitment to innovation, APELOA offers a diverse portfolio of products, including oncology medications and cardiovascular treatments, distinguished by their rigorous quality standards and competitive pricing. The company has achieved significant milestones, including numerous certifications and partnerships that enhance its market position. Recognised for its dedication to research and development, APELOA continues to contribute to global healthcare solutions, solidifying its reputation as a trusted name in the pharmaceutical sector.
DitchCarbon Score
How does APELOA's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
APELOA's score of 19 is lower than 87% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
APELOA's reported carbon emissions
As of 2024, APELOA has not disclosed specific carbon emissions data, including Scope 1, 2, or 3 emissions. The organisation, headquartered in China (CN), has reported a revenue of approximately USD 1.65 billion but has not provided any absolute emissions figures in kg CO2e. APELOA has not set any reduction targets or climate pledges, indicating a lack of formal commitments to reduce carbon emissions at this time. The absence of disclosed emissions data and reduction initiatives suggests that APELOA may still be in the early stages of developing a comprehensive climate strategy. It is important to note that emissions data from APELOA is not cascaded from any parent or related organisation, and all performance metrics are sourced directly from Apeloa Pharmaceutical Co., Ltd. As the company progresses, stakeholders may look for future disclosures regarding emissions and climate commitments.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
APELOA is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
